Prilago. · PDF p.37 Excerpt

COMBINED STATEMENT OF FIDUCIARY NET POSITION
AS OF JUNE 30, 2025, WITH SUMMARIZED
FINANCIAL TOTALS FOR 2024 - (IN $ THOUSANDS)

	CORP HEALTH INS	CORP-AOC PENSION	CORP-AOC HEALTH INS	2025 COMBINED TOTAL	† 2024 COMBINED TOTAL
ASSETS					
Cash and Cash Equivalents	$ 5,054	$ 26,991	$ 572	$ 794,063	$ 1,487,769
Other Assets	—	104	—	2,945	2,669
RECEIVABLES					
Member Contributions	—	345	—	4,402	6,197
Employer Contributions	—	2,248	—	40,521	48,088
Health Insurance Contributions	—	—	47	209	335
Court Fees	—	—	—	16	379
Interest and Dividends	287	1,505	32	44,002	50,223
Investment Sales	6	33	1	970	129,415
Other	2	11	—	756	694
Total Receivables	**295**	**4,142**	**80**	**90,876**	**235,331**
INVESTMENTS AT FAIR VALUE					
U.S. Public Equity	36,861	193,379	4,173	5,655,488	4,983,830
International Public Equity	25,821	135,459	2,923	3,961,592	3,323,287
Global Private Equity	37,184	195,073	4,209	5,705,039	4,984,461
Other Assets (Capital Appreciation)	—	—	—	—	157,104
Core Bonds	14,037	73,639	1,589	2,153,623	2,050,297
Private Credit	26,718	140,169	3,024	4,099,327	3,108,616
Other Assets (Contractual Income)	2,167	11,369	245	332,477	532,172
Diversifying Strategies	9,705	50,917	1,099	1,489,107	1,049,123
Total Investments	**152,493**	**800,005**	**17,262**	**23,396,653**	**20,188,890**
Securities Lending Collateral	6,652	34,897	753	1,020,585	1,690,585
CAPITAL ASSETS, AT COST, NET OF ACCUMULATED DEPRECIATION	—	**907**	—	**26,489**	**20,792**
TOTAL ASSETS	**164,494**	**867,046**	**18,667**	**25,331,611**	**23,626,036**
LIABILITIES					
Accrued Accounts Payable	—	60	—	701	1,348
Investment Purchases Payable	33	175	4	5,121	28,183
Securities Lending Collateral	6,652	34,897	753	1,020,585	1,690,585
Other Liabilities	—	429	—	12,091	11,455
Total Liabilities	**6,685**	**35,561**	**757**	**1,038,498**	**1,731,571**
FIDUCIARY NET POSITION RESTRICTED FOR PENSIONS AND OPEB BENEFITS	**$ 157,809**	**$ 831,485**	**$ 17,910**	**$ 24,293,113**	**$ 21,894,465**

† Prior year numbers conform to current year presentation.

** The accompanying notes are an integral part of these financial statements.*

Note: Certain amounts in the 2024 columns have been reclassified for comparative purposes to conform with the presentation for fiscal year 2025. The reclassifications have no effect on the previously reported Fiduciary Net Position Restricted or Changes in Fiduciary Net Position.